pH值对人参皂苷溶出影响规律的液质联用研究

采用液质联用(HPLC-ESI-MSn)技术, 对不同pH值(2.4~11.2)条件下人参皂苷的溶出变化规律进行了系统研究, 并提出了不同人参皂苷化合物的特征质谱裂解规律. 实验结果表明, 中性及碱性溶液对人参皂苷的溶出影响不大, 仅仅在溶出总量上有所差别; 而酸性是影响人参皂苷溶出的一个主要因素, 随着水溶液酸性的增强(pH<4), 人参皂苷溶出的种类明显减少, 表明较强酸性条件下人参皂苷的溶出受到了抑制.     

人参中稀有皂苷临界二氧化碳超提取

针对人参稀有皂苷极性较小的特点,选择超临界二氧化碳流体(SFE-CO2)技术进行提取,最佳提取实验条件为:压力35 MPa,温度50 ℃,夹带剂为70%乙醇,夹带剂用量为1.7 mL/g。 利用高效液相色谱 电喷雾质谱联用分析方法分析其萃取产物,证明该提取方法的提取效率与超声提取接近,且该方法具有环境友好的特点。     

人参中人参皂苷的直接高压微波辅助降解

采用高效液相色谱-电喷雾质谱联用法测定了人参提取液中的人参皂苷. 考察了天然人参皂苷发生降解的条件, 同时研究了单体人参皂苷Rg1, Re, Rb1, Rc, Rb2和Rd的降解, 并对降解产物进行了分析. 结果表明, 随着提取压力的升高, 提取液中天然人参皂苷的含量逐渐减少, 同时产生多种次级人参皂苷. 当微波提取压力达到600 kPa, 提取时间为10 min时, 提取液中的主要天然人参皂苷达到完全降解, 次级人参皂苷Rg3含量达到最高. 在单体人参皂苷Rb1, Rc, Rb2和Rd的降解产物中均得到人参皂苷Rg3.     

人参二醇类皂苷的生物转化动态及人参稀有皂苷C-K或F2的制备

为了低成本有效制备人参稀有皂苷C-K或F₂, 将A. niger g.848菌酶用于转化含有人参皂苷(质量分数)分别为49.6% Rb₁, 25.9% Rd, 19.3% Rc和5.23% Rb₂的西洋参二醇混合皂苷. 霉菌发酵时, 采用人参二醇皂苷诱导物比人参提取液诱导物的产酶总活力提高10%~15%. 所产的2种诱导酶均能水解人参二醇皂苷的3-O-和20-O-多种糖基, 均为人参皂苷酶Ⅰ型; 但是人参二醇皂苷诱导物所产酶几乎全部转化人参二醇皂苷为C-K, 而人参提取液诱导物所产酶则残留中间产物. 使用黑曲霉人参二醇皂苷诱导所产酶, 在转化西洋参二醇皂苷的动态研究中发现, 酶反应1.5~2.5 h, 主要为产物F₂; 酶反应12 h后, 主要产物为C-K皂苷. 基于此, 40 g人参二醇类皂苷在45 ℃粗酶反应24 h, 经处理得到含C-K质量分数为87%的23 g酶反应产物, C-K转化率达85%(摩尔分数). 用40 g西洋参二醇皂苷在45 ℃粗酶反应2.5 h, 经处理得到含有质量分数为58%的F₂和27%的C-K的26 g酶反应产物, F₂转化率为50.4%, C-K转化率为29.5%. 通过人参二醇皂苷诱导的黑曲霉粗酶转化人参二醇类皂苷动态研究, 建立了C-K转化率为85%, F₂转化率为50%的制备方法, 为大批量制备提供了基础依据.     

人参中皂苷类化合物的HPLC-ESI MS研究

利用高效液相色谱与电喷雾质谱联用技术分析鉴定了人参粗提物中人参皂苷类化合物。实验采用反相C18色谱柱,二元线性梯度洗脱（0．2％的醋酸水溶液和乙腈）,分离并检测了人参中的皂苷类化合物：通过与电喷雾质谱的联用和质谱的源内CID技术获得了其中主要色谱峰相对应化合物的相对分子质量和结构信息。     

HPLC-MS结合多元统计分析区分人参产地及筛选皂苷类标志物

利用高效液相色谱-质谱联用(HPLC-MS)技术结合多元统计分析方法, 区分中国人参主产区5个不同产地的45个人参样本, 筛选出差异性皂苷类标志物. 根据人参总皂苷在反相C₁₈色谱柱中的洗脱顺序, 结合串联质谱分析和标准品比对, 在提取的人参总皂苷中鉴定出15种原人参三醇型、 24种原人参二醇型和2种齐墩果酸型共41种皂苷. 对人参总皂苷的HPLC-MS全扫描数据进行了多元统计分析. 正交偏最小二乘-判别分析(OPLS-DA)结果表明, 所建立的分析模型具有良好的数据描述能力和预测能力. 所有人参样本能够根据产地被区分, 并筛选得到同时区分5个产地的差异性皂苷类组分18种; 能够区分任意2个产地人参样本的差异性组分主要为在人参中含量较高的人参皂苷Rb1, Rg1, Re, Rc, Rd, Ro和m-Rb1等. 分层聚类分析(HCA)结果显示, 黑龙江和吉林两省的样本能够独自聚类, 但是绥化市的样本更接近于吉林省. 初步推断原因为绥化市地理位置较接近吉林省, 两地人参生长环境相似并可能存在种质资源交换.     

液质联用测定人参与五灵脂、莱菔子配伍的人参皂苷

采用液质联用(HPLC-ESI-MSn)技术,对不同比例的人参、五灵脂和人参、莱菔子的水煎液、沉淀和药渣进行研究,共鉴定了10种人参皂苷,并对这10种人参皂苷配伍前后的变化进行了系统的研究。实验结果表明,在共煎液中,除Ro外,其它皂苷的含量都有所下降。五灵脂或莱菔子的加入对人参皂苷的影响不同,莱菔子影响人参皂苷的溶出,而与五灵脂配伍,部分人参皂苷生成沉淀。     

泡沫浮选-固相提取分离富集三七提取液中的人参皂苷

采用泡沫浮选-固相提取联用法,分离富集三七中的R1,Rg1,Re,Rc,Rb2,Rb3,Rd和Rb1,并用液相色谱法测定其含量,检测灵敏度和选择性都有所提高.对泡沫浮选过程的载气流量、浮选时间、样品溶液pH值和固相提取柱的洗脱条件进行了优化.原人参二醉型皂苷R1,Rc,Rb2,Rb3,Rd和Rb1的回收率在85.0%9...     

离子液体-非极性溶剂微波提取法在人参化学成分研究中的应用

以离子液体作为微波吸收介质建立了离子液体-非极性溶剂微波提取法,对人参中的化学成分进行了提取,并将该法与固体微波吸收介质-非极性溶剂微波提取法、极性溶剂微波提取法以及混合溶剂微波提取法进行了对比.结果表明,极性溶剂提取的主要化学成分为极性化合物,而固体微波吸收介质-非极性溶剂微波提取法与离子液体-非极性溶剂微波提取法相比,提取所得的化学成分并无明显差别,说明离子液体是一种较好的微波吸收介质和能量传递材料.所建立的方法具有提取时间短、操作简单及绿色环保等优点,且对后期分析无明显影响,是快速提取化学成分的理想方法.     

人参皂苷与环糊精包合物的研究进展

人参皂苷是从人参、西洋参和三七中提取的主要活性成分,其药效价值相当高,但因其在水中几乎不溶,生物利用度极低,因此极大的限制了其在临床上的应用.环糊精具有独特的性质,其"腔内疏水、腔外亲水",可以选择性的包合人参皂苷等客体分子.环糊精与人参皂苷形成包合物后可以改变客体分子的某些物理化学性能,如水溶性、稳定性以及光学性质等,以此来提高其生物利用度.     

Comparative analysis on microbial and rat metabolism of ginsenoside Rb1 by high-performance liquid chromatography coupled with tandem mass spectrometry

Ginsenoside Rb1 is an active protopanaxadiol saponin from Panax species. In order to compare the similarities and differences of microbial and mammalian metabolisms of ginsenoside Rb1, the microbial transformation by Acremonium strictum and metabolism in rats were comparatively studied. Microbial transformation of ginsenoside Rb1 by Acremonium strictum AS 3.2058 resulted in the formation of eight metabolites. Ten metabolites (M1-M10) were detected from the in vivo study in rats and eight of them were identified as the same compounds as those obtained from microbial metabolism by liquid chromatography-tandem mass spectrometry analysis and comparison with reference standards obtained from microbial metabolism. Their structures were identified as ginsenoside Rd, gypenoside XVII, 20(S)-ginsenoside Rg3, 20(R)-ginsenoside Rg3, ginsenoside F2, compound K, 12beta-hydroxydammar-3-one-20(S)-O-beta-d-glucopyranoside, and 25-hydroxyl-(E)-20(22)-ene-ginsenoside Rg3, respectively. The structures of the additional two metabolites were tentatively characterized as 20(22),24-diene-ginsenoside Rg3 and 25-hydroxyginsenoside Rd by HPLC-MS/MS analysis. M7-M10 are the first four reported metabolites in vivo. The time course of rat metabolism of ginsenoside Rb1 was also investigated.     

超声波半微量提取快速测定人参总皂甙

应用超声波半微量提取法建立了人参中总皂甙的快速测定方法。与索氏提取测定法相比 ,本方法测定单一样品所用时间由 2～ 3个工作日缩短到 1～ 2h ,样品用量由 2 .0g减少到 0 .1g ,并节省大量试剂 ,工作效率提高数 1 0倍。与索氏法对照分析表明 ,本法可满足人参中总皂甙的快速测定要求。     

Determination of pseudo‐ginsenoside GQ in human plasma by high performance liquid chromatography–tandem mass spectrometry

A specific, sensitive and rapid method based on high performance liquid chromatography coupled to tandem mass spectrometry (HPLC‐MS/MS) was developed for the determination of pseudo‐ginsenoside GQ in human plasma. Liquid–liquid extraction was used to isolate the analyte from biological matrix followed by injection of the extracts onto a C₈ column with isocratic elution. Detection was carried out on a triple quadrupole tandem mass spectrometer (API‐4000 system) in multiple reaction monitoring mode using negative electrospray ionization. The mobile phase consisted of methanol–10 mm ammonium acetate (90:10, v/v) and the flow rate was 0.3 mL/min. The method was validated over the concentration range of 5.0–5000.0 ng/mL for plasma. Inter‐ and intra‐day precisions (relative standard deviation) were all within 15% and the accuracy (relative error) was ≤9.4%. The lower limit of quantitation was 5.0 ng/mL. The pseudo‐ginsenoside GQ was stable after 8 h at room temperature, 24 h at autosampler and three freeze–thaw cycles (from ?30 to 25 °C). The method was successfully applied to the pharmacokinetic study of pseudo‐ginsenoside GQ in healthy Chinese volunteers. Copyright © 2013 John Wiley & Sons, Ltd.     

Pharmacokinetics and bioavailability study of ginsenoside Rk1 in rat by liquid chromatography/electrospray ionization tandem mass spectrometry

Ginsenoside Rk1 (Rk1) exhibited various potent biological activities. However, its pharmacokinetic profile in vivo remains unclear. In the present study, a simple and sensitive liquid chromatography tandem mass spectrometry method was developed and validated for determination of Rk1 in rat plasma and applied in a pharmacokinetic study. The sample was precipitated with acetonitrile and separated on a Zorbax Eclipse XDB C18 column (50 × 2.1 mm, 1.8 μm). The mobile phase was composed of 0.1% formic acid in water and acetonitrile at a flow rate of 0.4 mL/min. Rk1 and internal standard (ginsenoside Rg3) were quantitatively monitored with precursor‐to‐product ion transitions of m/z 765.4 → 441.5 and m/z 783.5 → 621.4, respectively. The assay was linear over the concentration range of 5–1000 ng/mL (r > 0.99) with the LLOQ of 5 ng/mL. Other parameters including intra‐ and inter‐day precision and accuracy, extraction recovery and matrix effect were within the acceptable limits. The analyte was stable under the tested storage conditions. The validated method has been successfully applied to a pharmacokinetic study of Rk1 in rat plasma after intravenous (5 mg/kg) and oral (25 mg/kg, 50 mg/kg) administration. After oral administration, Rk1 could be detected in blood at 30 min and reached the highest concentration at 4.29~4.57 h. Our results demonstrated that Rk1 showed low clearance, moderate half‐life (3.09–3.40 h) and low bioavailability (2.87–4.23%). The study will provide information for the further application of Rk1.     

Changes in intestinal microbiota affect metabolism of ginsenoside Re

Ginsenoside Re, an active ingredient in Panax ginseng, is widely used as a therapeutic and nutriment. The intestinal microbiota plays crucial roles in modulating the pharmacokinetics and pharmacological actions of ginsenoside Re. The aim of this study was to explore the relationship between bacterial community variety and the metabolic profiles of ginsenoside Re. We developed two models with intestinal dysbacteriosis: a pseudo‐germ‐free model induced by a nonabsorbable antimicrobial mixture (ATM), and Qi‐deficiency model established via over‐fatigue and acute cold stress (OACS). First, the bacterial community structures in control, ATM and OACS rats were compared via 16S ribosomal RNA amplicon sequencing. Then, the gut microbial metabolism of ginsenoside Re was assessed qualitatively and quantitatively in the three groups by UPLC‐Q‐TOF/MS and HPLC‐TQ‐MS, respectively. Ten metabolites of ginsenoside Re were detected and tentatively identified, three of which were novel. Moreover, owing to significant differences in bacterial communities, deglycosylated products, as the main metabolites of ginsenoside Re, were produced at lower levels in ATM and OACS models. Importantly, the levels of these deglycosylated metabolites correlated with alterations in Prevotella, Lactobacillus and Bacteroides populations, as well as glycosidase activities. Collectively, biotransformation of ginsenoside Re is potentially influenced by regulation of the composition of intestinal microbiota and glycosidase activities.     

Metabolite profiling of ginsenoside Rg1 after oral administration in rat

The goal of this study is to investigate the biotransformation of ginsenoside Rg₁ in vivo. A highly sensitive and specific LC‐MS/MS method was developed and used for metabolite identification in rat feces and urine after oral administration of ginsenoside Rg₁. Four metabolites of Rg₁ were detected in rat feces and three metabolites of Rg₁ were detected in rat urine. Deglycosylation and oxygenation were found to be the major metabolic pathways of ginsenoside Rg₁ after oral administration in rat. Except for the reported metabolites Rh₁ and protopanaxatriol, mono‐oxygenated Rg₁ and mono‐oxygenated protopanaxatriol were detected for the first time after oral administration of Rg₁. The in vivo metabolite profiling of ginsenoside Rg₁ in rat was proposed. Viewed collectively, Rg₁ was metabolized to mono‐oxygenated Rg₁, Rh₁, protopanaxatriol and the secondary metabolite mono‐oxygenated protopanaxatriol in rat. Copyright © 2014 John Wiley & Sons, Ltd.     

Electrochemical characterization of hydrogels for biomimetic applications

Hydrogels are increasingly being recognized as having potential in bio‐compatible applications. In previous work, we investigated the feasibility of poly(ethylene glycol)‐dimethacrylate (PEG‐1000‐DMA) and poly(ethylene glycol)‐diacrylate (PEG‐400‐DA) polymerized using either a chemical initiator (C) or a photoinitiator (P) to encapsulate and stabilize biomimetic membranes for novel separation technologies or biosensor applications. In this paper, we have investigated the electrochemical properties of the hydrogels used for membrane encapsulation. Specifically, we studied the crosslinked hydrogels by using electrochemical impedance spectroscopy (EIS), and we demonstrated that chemically crosslinked hydrogels had lower values for the effective electrical resistance and higher values for the electrical capacitance compared with hydrogels with photoinitiated crosslinking. Transport numbers were obtained using electromotive force measurements and demonstrated that at low salt concentrations, both PEG‐400‐DA‐C and PEG‐400‐DA‐P hydrogels presented an electropositive character whereas PEG‐1000‐DMA‐P was approximately neutral and PEG‐1000‐DMA‐C showed electronegative character. Sodium transport numbers approached the bulk NaCl electrolyte value at high salt concentrations for all hydrogels, indicating screening of fixed charges in the hydrogels. The average salt diffusional permeability 〈P_s〉 and water permeability 〈P_w〉 were found to correlate with EIS results. Both PEG‐1000‐DMA‐C and PEG‐400‐DA‐C had higher 〈P_s〉 and 〈P_w〉 values than PEG‐1000‐DMA‐P and PEG‐400‐DA‐P hydrogels. In conclusion, our results show that hydrogel electrochemical properties can be controlled by the choice of polymer and type of crosslinking used and that their water and salt permeability properties are congruent with the use of hydrogels for biomimetic membrane encapsulation. Copyright © 2011 John Wiley & Sons, Ltd.     

Enhancing effect of borneol on pharmacokinetics of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 in healthy volunteers after oral administration of compound Danshen dropping pills

Borneol (Bingpian), a monoterpenoid pharmaceutical ingredient, is commonly used as a main composition in traditional Chinese medicine preparations such as compound Danshen dropping pills (CDDP) and has also been approved by the U.S. Food and Drug Administration as a flavoring substance or adjuvant in food. Borneol plays a regulating and guiding role as a messenger drug in CDDP. However, the effect of borneol on the pharmacokinetics of the components of CDDP in human plasma is unclear. In this study, we investigate the effects of borneol on the pharmacokinetics of ginsenoside Rb₁ (Rb₁), ginsenoside Rg₁ (Rg₁), and notoginsenoside R₁ (NR₁) in CDDP. We used a double-cycle crossover-administration model in 12 healthy male volunteers, administered CDDP with borneol (drug T) and without borneol (drug R). The selective response monitoring mode was used for MS quantification in the positive mode. As a result, we found that borneol could significantly affect the pharmacokinetic parameters of notoginsenosides and increase the absorption and systemic exposure of Rb₁, Rg₁, and NR₁ in human plasma by ~1.85–3.71 times.     

高效液相色谱-飞行时间质谱联用法分析人参及人参皂苷与山楂配伍过程中的水解行为

利用高效液相色谱-飞行时间质谱联用的方法,分别对人参配伍山楂前后人参皂苷的变化进行分析,同时对人参皂苷Re、Rg1、Rb1、Rd与山楂配伍的水解规律进行系统研究,并与单独煎煮液、仿山楂配伍pH值煎煮液的水解产物进行比较,结果发现人参与山楂配伍后人参皂苷Rg1、Rb1含量明显减少,而人参皂苷Re、Rd、Rg2、Rg3、F2、Rh1含量明显增加,其中人参皂苷Re与山楂配伍后水解产物为人参皂苷20(R)-Rg2、20(S)-Rg2,仿山楂配伍pH值水解产物为人参皂苷20(R)-Rg2、20(S)-Rg2、Rg4、Rg6;人参皂苷Rg1与山楂配伍后水解产物为20(S)-Rh1、20(R)-Rh1,仿山楂pH值水解产物为20(S)-Rh1、20(R)-Rh1、Rh4、Rk3;人参皂苷Rb1与山楂配伍后水解产物为Rd、20(S)-Rg3,仿山楂pH值水解产物为F2、20(S)-Rg3;人参皂苷Rd与山楂配伍后水解产物为F2、20(S)-Rg3、20(R)-Rg3,仿山楂pH值水解产物为20(S)-Rg3、20(R)-Rg3。研究表明,不同人参皂苷和山楂配伍后与仿山楂pH值的水解产物并不相同,人参与山楂配伍改变了人参皂苷成分的种类及含量。本研究为临床方剂中人参与山楂配伍后成分的变化提供物质基础数据。     

Determination of pharmaceuticals in biosolids using accelerated solvent extraction and liquid chromatography/tandem mass spectrometry

An analytical method was developed to quantitatively determine pharmaceuticals in biosolid (treated sewage sludge) from wastewater treatment plants (WWTPs). The collected biosolid samples were initially freeze dried, and grounded to obtain relatively homogenized powders. Pharmaceuticals were extracted using accelerated solvent extraction (ASE) under the optimized conditions. The optimal operation parameters, including extraction solvent, temperature, pressure, extraction time and cycles, were identified to be acetonitrile/water mixture (v/v 7:3) as extraction solvent with 3 extraction cycles (15 min for each cycle) at 100 °C and 100 bars. The extracts were cleaned up using solid-phase extraction followed by determination by liquid chromatography coupled with tandem mass spectrometry. For the 15 target pharmaceuticals commonly found in the environment, the overall method recoveries ranged from 49% to 68% for tetracyclines, 64% to 95% for sulfonamides, and 77% to 88% for other pharmaceuticals (i.e. acetaminophen, caffeine, carbamazepine, erythromycin, lincomycin and tylosin). The developed method was successfully validated and applied to the biosolid samples collected from WWTPs located in six cities in Michigan. Among the 15 target pharmaceuticals, 14 pharmaceuticals were detected in the collected biosolid samples. The average concentrations ranged from 2.6 μg/kg for lincomycin to 743.6 μg/kg for oxytetracycline. These results indicated that pharmaceuticals could survive wastewater treatment processes, and accumulate in sewage sludge and biosolids. Subsequent land application of the contaminated biosolids could lead to the dissemination of pharmaceuticals in soil and water environment, which poses potential threats to at-risk populations in the receiving ecosystems.